17:55:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaMid Cap Helsinki
SektorHälsovård
IndustriLäkemedel & Handel
Oriola är en läkemedelskoncern med särskilt fokus inom distribution av läkemedel till andra aktörer inom branschen. Bolaget erbjuder tjänster till apotek och övriga läkemedelsbolag, vilket exempelvis innefattar förhandlingar med leverantörer och distribution av produkter. Idag innehas störst verksamhet inom Norden och Baltikum. Huvudkontoret ligger i Esbo.

Kalender

2023-10-27 Kvartalsrapport 2023-Q3
2023-07-21 Kvartalsrapport 2023-Q2
2023-04-27 Kvartalsrapport 2023-Q1
2023-03-21 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-03-16 Ordinarie utdelning OKDAV 0.04 EUR
2022-03-16 Ordinarie utdelning OKDBV 0.04 EUR
2022-03-15 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-10-27 Kvartalsrapport 2021-Q3
2021-07-20 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-17 Ordinarie utdelning OKDAV 0.03 EUR
2021-03-17 Ordinarie utdelning OKDBV 0.03 EUR
2021-03-16 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-04-24 Kvartalsrapport 2020-Q1
2020-03-18 Ordinarie utdelning OKDAV 0.09 EUR
2020-03-18 Ordinarie utdelning OKDBV 0.09 EUR
2020-03-17 Årsstämma 2020
2020-02-07 Bokslutskommuniké 2019
2019-07-17 Kvartalsrapport 2019-Q2
2019-03-20 Ordinarie utdelning OKDBV 0.09 EUR
2019-03-20 Ordinarie utdelning OKDAV 0.09 EUR
2019-03-19 Årsstämma 2019
2018-11-01 Kvartalsrapport 2018-Q3
2018-07-18 Kvartalsrapport 2018-Q2
2018-04-27 Kvartalsrapport 2018-Q1
2018-03-20 Ordinarie utdelning OKDAV 0.09 EUR
2018-03-20 Ordinarie utdelning OKDBV 0.09 EUR
2018-03-19 Årsstämma 2018
2018-02-13 Bokslutskommuniké 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-07-21 Kvartalsrapport 2017-Q2
2017-04-28 Kvartalsrapport 2017-Q1
2017-03-15 Ordinarie utdelning OKDBV 0.14 EUR
2017-03-15 Ordinarie utdelning OKDAV 0.14 EUR
2017-03-14 Årsstämma 2017
2017-02-13 Bokslutskommuniké 2016
2016-10-20 Kvartalsrapport 2016-Q3
2016-07-19 Kvartalsrapport 2016-Q2
2016-04-22 Kvartalsrapport 2016-Q1
2016-03-15 Ordinarie utdelning OKDAV 0.13 EUR
2016-03-15 Ordinarie utdelning OKDBV 0.13 EUR
2016-03-14 Årsstämma 2016
2016-02-05 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-09-09 Kapitalmarknadsdag 2015
2015-07-17 Kvartalsrapport 2015-Q2
2015-04-23 Kvartalsrapport 2015-Q1
2015-03-31 Ordinarie utdelning OKDAV 0.00 EUR
2015-03-31 Ordinarie utdelning OKDBV 0.00 EUR
2015-03-30 Årsstämma 2015
2015-02-06 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-07-24 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-03-25 Ordinarie utdelning OKDAV 0.00 EUR
2014-03-25 Ordinarie utdelning OKDBV 0.00 EUR
2014-03-24 Årsstämma 2014
2014-02-07 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-07-25 Kvartalsrapport 2013-Q2
2013-04-25 Kvartalsrapport 2013-Q1
2013-03-21 Ordinarie utdelning OKDAV 0.09 EUR
2013-03-21 Ordinarie utdelning OKDBV 0.09 EUR
2013-03-20 Årsstämma 2013
2013-02-07 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-07-26 Kvartalsrapport 2012-Q2
2012-04-26 Kvartalsrapport 2012-Q1
2012-03-27 Ordinarie utdelning OKDBV 0.08 EUR
2012-03-27 Ordinarie utdelning OKDAV 0.08 EUR
2012-03-26 Årsstämma 2012
2012-02-09 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-04 Kvartalsrapport 2011-Q2
2011-04-07 Ordinarie utdelning
2011-04-07 Bonusutdelning
2011-04-07 Bonusutdelning
2011-04-07 Ordinarie utdelning
2010-04-08 Ordinarie utdelning
2010-04-08 Ordinarie utdelning
2009-04-17 Ordinarie utdelning
2009-04-17 Ordinarie utdelning
2008-03-18 Ordinarie utdelning
2008-03-18 Ordinarie utdelning
2007-03-14 Ordinarie utdelning
2007-03-14 Ordinarie utdelning
2022-10-03 11:15:00

Oriola Corporation Insider information 3 October 2022 at 12.15 p.m.

Oriola and Euroapotheca have finalized the combining of Kronans Apotek and Apoteksgruppen into a new company

Oriola Corporation and Euroapotheca have finalized the combining of Kronans Apotek and Apoteksgruppen into a new jointly owned company. The transaction supports Oriola in its transformation as it focuses on being an infrastructure company of pharmaceuticals and healthcare distribution and providing services to pharmaceutical companies and pharmacies.

The new company is owned 50/50 percent equally by Oriola and Euroapotheca. The transaction is estimated to create annual run-rate synergies of approximately EUR 25 million on EBITDA level. The synergies are expected to realise in full by the end of the third year from closing.

The transaction is expected to have a negative impact of approximately EUR 30 million on the consolidated net profit of Oriola Group, including estimated translation differences and transaction related costs, in the fourth quarter of 2022. Customary closing adjustments, changes in currency exchange rates and the timing of the closing have an impact on the estimate. Oriola classified Kronans Apotek as assets held for sale during first quarter of 2022, therefore its assets are not depreciated. This had a positive impact of EUR 10.2 million until the end of second quarter, and the impact will be higher by the end of third quarter. This will offset part of the negative impact on Oriola Group.

For the parent company, there will be a negative impact of approximately EUR 100 million on net profit, decreasing the parent company's distributable funds by an equal amount. As announced, 9 February 2022, Oriola is to receive a one-off cash contribution of approximately EUR 24 million from Euroapotheca for reaching the 50/50 percent ownership in the new company.

The financial impact of the transaction will materialise and be specified in the fourth quarter of 2022 and reported in Oriola's full year financial report 2022.

Starting from the fourth quarter of 2022, Oriola will report the new company as an associated company under the equity method and present the associated company's result above the EBIT line in the consolidated financial statements.

Oriola Corporation

Further information

Mikael Wegmüller
VP, Communications and Sustainability
Tel. +358 040 776 2314
email: mikael.wegmuller@oriola.com

Distribution
Nasdaq Helsinki
Key media

Released by:
Oriola Corporation
Corporate Communications
Orionintie 5
FI-02200 Espoo
www.oriola.com